Proof of Concept Study of Cognitive Improvement in Patients With Schizophrenia

Completed · Phase 2

Conditions studied: Schizophrenia

In brief

The purpose of this study is to demonstrate that AZD3480 improves cognition in patients with stable schizophrenia who are being treated with an atypical antipsychotic and who are active cigarette smokers, to assess the safety and tolerability of AZD3480 and to define the optimal dose(s) to be used in future trials.

Key facts

Study ID
NCT00528905
Run by
AstraZeneca
People needed
400
Starts
2007-08-01
Expected to finish
2008-11-01
Last updated by the study team
2008-11-25

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.